{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:38:40Z","timestamp":1791362320385,"version":"4.3.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T00:00:00Z","timestamp":1470096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0160485","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T17:36:49Z","timestamp":1470159409000},"page":"e0160485","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"11","author":[{"given":"Zhijuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","article-title":"The changing landscape of smoldering multiple myeloma: a European perspective","volume":"21","author":"J Caers","year":"2016","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"RL Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"GJ Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm0902-1039c","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"H Dong","year":"2002","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance","volume":"74","author":"FM Marincola","year":"2000","journal-title":"Adv Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Y Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.4254\/wjh.v7.i23.2449","article-title":"Programmed death-1\/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy","volume":"7","author":"ML Salem","year":"2015","journal-title":"World J Hepatol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"H Nishimura","year":"1999","journal-title":"Immunity"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"J Liu","year":"2007","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"RH Thompson","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"SL Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"H Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"J Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"RJ Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"SM Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"J Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"A Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"JS Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"MB Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0971-5916.180197","article-title":"Immune based therapy for melanoma","volume":"143","author":"R Ancuceanu","year":"2016","journal-title":"Indian J Med Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/ijc.23664","article-title":"Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy","volume":"123","author":"AA Brozyna","year":"2008","journal-title":"Int J Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1152\/physrev.00044.2003","article-title":"Melanin pigmentation in mammalian skin and its hormonal regulation","volume":"84","author":"A Slominski","year":"2004","journal-title":"Physiol Rev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ijc.24005","article-title":"Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells","volume":"124","author":"A Slominski","year":"2009","journal-title":"Int J Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"17844","DOI":"10.18632\/oncotarget.7528","article-title":"Melanin content in melanoma metastases affects the outcome of radiotherapy","volume":"7","author":"AA Brozyna","year":"2016","journal-title":"Oncotarget"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.humpath.2013.02.022","article-title":"Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma","volume":"44","author":"AA Brozyna","year":"2013","journal-title":"Hum Pathol"},{"key":"ref28","first-page":"94","article-title":"The future of systemic therapy of melanoma: combinations, predictive biomarkers","volume":"29","author":"AA Tarhini","year":"2015","journal-title":"Oncology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"D Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Y Ishida","year":"1992","journal-title":"EMBO J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/geno.1994.1562","article-title":"Structure and chromosomal localization of the human PD-1 gene (PDCD1)","volume":"23","author":"T Shinohara","year":"1994","journal-title":"Genomics"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"ME Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"LM Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"J Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref35","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib Keynote-012 study","author":"R Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","volume":"100","author":"S Gandini","year":"2016","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0160485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T02:23:15Z","timestamp":1568254995000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0160485"}},"subtitle":[],"editor":[{"given":"Andrzej T","family":"Slominski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,2]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0160485","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,2]]}}}